Synthetic Compound NES: A Drug Target and Biomarker (G10763)

Target Name: NES

NCBI ID: G10763

Content of Review Report on NES Target / Biomarker

NES

Other Name(s): Nbla00170 | Nestin | NEST_HUMAN | nestin

Synthetic Compound NES: A Drug Target and Biomarker

NES (N-acetyl-L-tetradecylamine) is a drug target and a biomarker that is being studied for its potential therapeutic effects in various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. NES is a synthesized compound that is derived from tryptophan, an amino acid that is found in many proteins in the human body.

The synthesis of NES began in the 1960s by the Japanese scientist Kiyokazu Kikuchi. Kikuchi was interested in the tryptophan pathway, which is the biosynthesis of tryptophan from tryptophan precursors, and he wanted to investigate the metabolism of tryptophan to NES. He synthesized NES and found that it had a number of unique properties, including a high affinity for binding to a specific protein called TrkB, which is a G protein-coupled receptor on cancer cells.

Since then, NES has been extensively studied for its potential therapeutic effects in various diseases. In cancer, NES has been shown to have anti-tumor effects by inhibiting the growth of cancer cells and triggering apoptosis, or cell death, in these cells. This is thought to occur through the inhibition of TrkB, which is known to play a role in cell survival and proliferation.

NES has also been shown to be a potential biomarker for various psychiatric disorders, including depression and anxiety. This is thought to occur through its effects on the levels of certain neurotransmitters, such as serotonin and dopamine, in the brain. For example, NES has been shown to increase the levels of serotonin in the brain, which is a neurotransmitter that is involved in mood regulation, and to reduce the levels of dopamine, which is involved in pleasure and reward.

In addition to its potential therapeutic and biomarker applications, NES is also of interest to researchers because of its unique chemical structure. NES is a tryptophan derivative that has a helical arrangement and a fused aromatic ring. This structural feature is unique and not found in any other compound, and it has been shown to have a number of unique properties, including a high affinity for binding to TrkB and a unique stability in a variety of conditions, such as high pH and high temperature.

Overall, NES is a drug target and biomarker that is being studied for its potential therapeutic and diagnostic applications in a variety of diseases. Its unique chemical structure and its effects on the levels of neurotransmitters in the brain make it an attractive candidate for further research. As research continues, it is likely that NES will emerge as a valuable tool for the treatment and diagnosis of various psychiatric and cancer diseases.

Protein Name: Nestin

Functions: Required for brain and eye development. Promotes the disassembly of phosphorylated vimentin intermediate filaments (IF) during mitosis and may play a role in the trafficking and distribution of IF proteins and other cellular factors to daughter cells during progenitor cell division. Required for survival, renewal and mitogen-stimulated proliferation of neural progenitor cells (By similarity)

The "NES Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NES comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets